Asston Pharmaceuticals Limited successfully concluded its board meeting on March 30, 2026, implementing significant leadership changes and corporate governance measures. The meeting, conducted from 03:00 P.M. to 04:00 P.M. via video conferencing at the registered office, resulted in the approval of key appointments and scheduling of an Extraordinary General Meeting.

Board Meeting Outcomes

The board meeting concluded with the successful implementation of all proposed agenda items under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Key Leadership Appointments

Mr. Sumit Pawar brings over 3 years of experience in finance and accounting management to his new role as Chief Financial Officer. As a Commerce graduate, he possesses understanding of diverse business processes and strategy development, with expertise expected to enhance the company's financial models and strategic planning capabilities. His association with the company is anticipated to provide operational and financial efficacy.

Mr. Yashvardhan Tupe, appointed as Additional Non-Executive Director, holds a Bachelor's degree in Mechanical Engineering and a Master of Science in Management and International Business. His strong academic background and relevant exposure, particularly aligned with operational and strategic aspects of the manufacturing industry, positions him to contribute effectively to the company's growth, governance framework, and long-term business strategy.

Independent Director Addition

Mr. Sandip Sharma's appointment as Additional Non-Executive Independent Director strengthens the board's independence. As a qualified Company Secretary with over two years of professional experience in corporate law, governance, and regulatory compliance, he has successfully cleared the Independent Director Examination conducted by the Indian Institute of Corporate Affairs and holds the Certificate of Independent Director. His expertise encompasses Companies Act, SEBI regulations, corporate governance frameworks, and secretarial standards.

Regulatory Compliance and EGM Planning

The company maintained strict adherence to regulatory requirements, with all appointments taking immediate effect from March 30, 2026. The board approved the Extraordinary General Meeting scheduled for April 28, 2026, at 12:30 PM through Video Conferencing or Other Audio Visual Means. Company Secretary and Compliance Officer Rishi Upadhaya signed the regulatory filing to BSE Limited, ensuring transparent communication and maintaining the company's commitment to regulatory compliance.

All appointed personnel confirmed no relationships with existing board directors, maintaining governance independence standards as required under SEBI regulations.

Asston pharmaceuticals Limited has formally appointed M/s Panchal S K and Associates as its new statutory auditors, effective February 27, 2026. The pharmaceutical company made this announcement through an official disclosure to BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Approval and Regulatory Compliance

The Board of Directors approved the appointment through a resolution passed by circulation, acting on the recommendation of the Audit Committee. The decision was made in accordance with Section 175 of the Companies Act, 2013, and related rules. The appointment is subject to approval from shareholders at the company's upcoming general meeting.

About the New Auditors

M/s Panchal S K and Associates brings substantial credentials to the role. The firm was established in 2017 and holds ICAI registration number 145989W along with Peer Review Certificate number 018089. Led by founder partner Swati Panchal, who has been a member of ICAI since 2012, the firm comprises young and dynamic professionals.

Firm Credentials and Experience

The audit firm's experience spans across various industries, working with clients ranging from small and medium enterprises to large corporations. This diverse portfolio reflects their expertise and commitment to delivering quality professional services.

Disclosure Timeline and Formal Communication

The company submitted its formal disclosure to BSE Limited on March 2, 2026, signed by Company Secretary and Compliance Officer Rishi Upadhaya. The disclosure explained that the submission timing was due to the Board's approval being received on Friday, February 27, 2026, after business hours, followed by weekend non-working days on February 28 and March 1, 2026.

Regulatory Framework

The appointment process adhered to multiple regulatory requirements, including provisions under the Companies Act, 2013, and SEBI regulations. The company confirmed that no relationships exist between the new auditors and the company's directors, ensuring independence in the audit function. The disclosure was made in accordance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with all required annexures forming an integral part of the intimation.